Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DAVITA INC. Director's Dealing 2015

Jan 6, 2015

30643_dirs_2015-01-06_2a46161c-4141-4ae1-9fd5-9c91cfcad3a6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DAVITA HEALTHCARE PARTNERS INC. (DVA)
CIK: 0000927066
Period of Report: 2014-01-02

Reporting Person: STAFFIERI MICHAEL DAVID (COO, Kidney Care)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-01-02 Common Stock M 17000 $31.70 Acquired 17000 Direct
2015-01-02 Common Stock F 7116 $75.74 Disposed 9884 Direct
2015-01-02 Common Stock S 9884 $75.5242 Disposed 0 Direct
2015-01-02 Common Stock M 80000 $34.515 Acquired 80000 Direct
2015-01-02 Common Stock F 36457 $75.74 Disposed 43543 Direct
2015-01-02 Common Stock S 43543 $75.8282 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-01-02 Stock Appreciation Rights $31.70 M 17000 Disposed 2015-03-31 Common Stock (17000) Direct
2015-01-02 Stock Appreciation Rights $34.515 M 80000 Disposed 2015-09-30 Common Stock (80000) Direct

Footnotes

F1: The sales reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2014.

F2: Represents the weighted average sale price of $75.5242. The range of prices for the sale of these shares was $75.47 - $75.60, rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: Represents the weighted average sale price of $75.8282. The range of prices for the sale of these shares was $75.60 - $76.31, rounded to the nearest hundredths. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.

F4: Stock Appreciation Rights, granted on 3/31/10, pursuant to the DaVita Inc. 2002 Equity Compensation Plan, (as amended and restated, the "DaVita HealthCare Partners Inc. 2011 Incentive Award Plan," effective June 6, 2011), which vested 33.3% on the second anniversary of the grant date, and 8.33% every 3 months thereafter.

F5: Stock Appreciation Rights, granted on 9/30/2010, pursuant to the DaVita Inc. 2002 Equity Compensation Plan, (as amended and restated, the "DaVita HealthCare Partners Inc. 2011 Incentive Award Plan," effective June 6, 2011), which vested 25% on the first anniversary of the grant date, then 6.25% every three months thereafter.